Markovitz Paul J
Case Western Reserve University, USA.
J Pers Disord. 2004 Feb;18(1):90-101. doi: 10.1521/pedi.18.1.90.32768.
This article reviews pharmacologic trials conducted between 2000 and 2003 directed at the treatment of borderline personality disorder, antisocial personality disorder, and schizotypal personality disorder. Atypical antipsychotics, antiepileptics, selective serotonin reuptake inhibitors, omega fatty acids, and opioid antagonists have all been studied in the treatment of borderline personality disorder with positive results. Atypical antipsychotics have been studied in both schizotypal personality disorder and antisocial personality disorder, again with encouraging outcome reports. Implications of personality changes in response to pharmacologic treatment are discussed. Based on the prevalence of these disorders and the burden they cause to afflicted individuals and society, further trials are unequivocally indicated.
本文回顾了2000年至2003年间针对边缘型人格障碍、反社会型人格障碍和分裂型人格障碍进行的药物试验。非典型抗精神病药物、抗癫痫药物、选择性5-羟色胺再摄取抑制剂、ω-脂肪酸和阿片类拮抗剂均已在边缘型人格障碍治疗中进行研究，并取得了积极成果。非典型抗精神病药物已在分裂型人格障碍和反社会型人格障碍治疗中进行研究，同样有令人鼓舞的结果报告。文中讨论了药物治疗引起人格变化的影响。鉴于这些疾病的患病率以及它们给患者个人和社会造成的负担，进一步试验显然是必要的。
